T-E Meds is a biotechnology company that specializes in the discovery and development of novel therapies for the treatment of cancer and other diseases. Our proprietary technology platforms are based on innovative "Multi-Arm Linkers" and proprietary bioconjugation methods, and can be applied in antibody-drug conjugates (ADCs) and antibody-radionuclide conjugates (ARCs). The company was founded by Dr. Tse Wen Chang, a renowned expert in entrepreneurship and new drug development, who co-founded Tanox, Inc., founded Immunwork, Inc., and invented anti-IgE therapy (Xolair).
T-E Meds' ADC/ARC technology platforms use an enzyme-free click reaction to generate site-specific conjugation ADC/ARCs with a high drug-to-antibody ratio (DAR), high reaction yield, and high purity. The dual-payload design is feasible to conjugate two different payloads to one single antibody molecule with one conjugation step. The "Drug Bundle," a unique payload/linker design based on Multi-Arm Linkers, allows multiple copies of payload molecules to be conjugated to the antibody at one conjugation site. The payload selection, payload number, cleavability of the linker, hydrophilicity of the Drug Bundle, and conjugation group/method are subjects to be selected for appropriated ADC designs. T-E Meds' innovative ADC / ARC technology platform can be considered best-in-class.
T-E Meds has a robust pipeline of drug candidates in various stages of discovery and preclinical development. Our lead product candidate, TE-1146, is an ADC designed to selectively target multiple myeloma cells and spare healthy tissue. In several animal models, TE-1146 demonstrated superior treatment efficacy compared to daratumumab/lenalidomide combo regimen. Currently, TE-1146 is in preclinical CMC development. Another promising product candidate, TE-1132, an ARC designed to selectively target pancreatic cancer cells, is in preclinical development. TE-1132 can be applied in SPECT/CT image diagnosis and radiotherapy. In several animal models, TE-1132 displayed strong potential in both diagnosis and therapy.
T-E Meds is actively raising funds to support the continuous development of our technology platforms and pipeline products. The company was recently spun-off from Immunwork, Inc. in November 2022 and is currently raising the first round of financing. We are open to discussing various types of collaborations, including platform licensing, drug product licensing, co-development, or other R&D collaborations.
Dr. Tse Wen Chang's extensive experience in entrepreneurship and new drug development has enabled T-E Meds to establish a strong foundation for innovative technology platforms and a de-risked pipeline. This, along with the company's best-in-class platforms, demonstrates our commitment to advancing the field of cancer therapy, as well as ADC / ARC drug discovery and development.
T-E Meds' ADC/ARC technology platforms use an enzyme-free click reaction to generate site-specific conjugation ADC/ARCs with a high drug-to-antibody ratio (DAR), high reaction yield, and high purity. The dual-payload design is feasible to conjugate two different payloads to one single antibody molecule with one conjugation step. The "Drug Bundle," a unique payload/linker design based on Multi-Arm Linkers, allows multiple copies of payload molecules to be conjugated to the antibody at one conjugation site. The payload selection, payload number, cleavability of the linker, hydrophilicity of the Drug Bundle, and conjugation group/method are subjects to be selected for appropriated ADC designs. T-E Meds' innovative ADC / ARC technology platform can be considered best-in-class.
T-E Meds has a robust pipeline of drug candidates in various stages of discovery and preclinical development. Our lead product candidate, TE-1146, is an ADC designed to selectively target multiple myeloma cells and spare healthy tissue. In several animal models, TE-1146 demonstrated superior treatment efficacy compared to daratumumab/lenalidomide combo regimen. Currently, TE-1146 is in preclinical CMC development. Another promising product candidate, TE-1132, an ARC designed to selectively target pancreatic cancer cells, is in preclinical development. TE-1132 can be applied in SPECT/CT image diagnosis and radiotherapy. In several animal models, TE-1132 displayed strong potential in both diagnosis and therapy.
T-E Meds is actively raising funds to support the continuous development of our technology platforms and pipeline products. The company was recently spun-off from Immunwork, Inc. in November 2022 and is currently raising the first round of financing. We are open to discussing various types of collaborations, including platform licensing, drug product licensing, co-development, or other R&D collaborations.
Dr. Tse Wen Chang's extensive experience in entrepreneurship and new drug development has enabled T-E Meds to establish a strong foundation for innovative technology platforms and a de-risked pipeline. This, along with the company's best-in-class platforms, demonstrates our commitment to advancing the field of cancer therapy, as well as ADC / ARC drug discovery and development.
Focus Areas
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
